The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Phase I, Randomised, Open-label, Cross-over, Single-centre Study in Healthy Male and Non-fertile Female Volunteers to Determine the Relative Bioavailability of the Phase II wet granulation tablet formulation compared to the Phase II/III roller compacted tablet formulation of AZD8931
- collapse An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
- collapse A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
- collapse A methodology study to support the future investigation of AZD2171 in patients with Acute Myeloid Leukaemia (AML)
- collapse Hepatocellular Carcinoma
- collapse A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
- collapse Warfarin Interaction Study
- collapse A phase 1, open label, dose seeking study of AZD2171 given daily orally in combination with selected chemotherapy regimens in patients with advanced incurable non-small cell lung cancer or colorectal cancer
- collapse Phase I Trial of AZD2171, an Orally Bioavailable Antiangiogenic Agent, in Pediatric Patients with Refractory
- collapse A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin) In Patients With Advanced Solid Tumours
